Why Most Antidepressants Fail for Chronic Pain: What 2024 Research Reveals

Chronic pain affects approximately one in five adults in the United States, representing a public health crisis that costs billions annually. For decades, physicians have prescribed antidepressants off-label to manage conditions like neuropathic pain, fibromyalgia, and chronic back pain. But groundbreaking research published in 2023 and 2024 is challenging this long-standing practice, revealing that most antidepressants simply don't work for pain relief.

A comprehensive review analyzing data from 156 clinical trials involving more than 25,000 adult participants has sent shockwaves through the medical community. The findings suggest that patients may be suffering uncomfortable side effects from medications with unproven benefits.

The Surprising Truth About Antidepressants and Pain Management

In 2021, U.K. health authorities recommended against using most medications for pain management except antidepressants. This decision prompted researchers to conduct one of the most thorough examinations of antidepressant efficacy ever undertaken.

The team analyzed 26 review papers covering eight classes of antidepressants across 22 different pain conditions. The results were eye-opening: only about 25% of the antidepressant-condition combinations showed any evidence of effectiveness. In the remaining 31 cases, antidepressants appeared either completely ineffective or the evidence was too weak to draw conclusions.

Dr. Giovanni Ferreira, PhD, a fellow at the University of Sydney's Institute for Musculoskeletal Health and lead author of the landmark study, emphasizes the need for nuance in prescribing practices. "A person is not just a pain condition," Ferreira explained. "The decision to use those drugs or not has to take into account not only the pain problem, but also the broader context of the individual."

SNRIs: The Only Class Showing Promise

Among the eight classes of antidepressants examined, serotonin-norepinephrine reuptake inhibitors (SNRIs) emerged as the most promising option for pain management. These medications work by increasing levels of both serotonin and norepinephrine in the brain, neurotransmitters involved in pain signal modulation.

Duloxetine (Cymbalta) stands out as the only FDA-approved antidepressant specifically for neuropathic pain conditions. It's indicated for:

Fibromyalgia
Chronic musculoskeletal pain
Diabetic peripheral neuropathic pain

The review found moderate certainty evidence that SNRIs can alleviate:

Back pain
Postoperative pain
Fibromyalgia
Neuropathic pain

However, researchers noted an important caveat: many SNRI efficacy studies were industry-sponsored. "These trials tend to present more optimistic results compared to trials done by independent investigators," Ferreira cautioned.

The TCA Problem: Most Prescribed, Least Effective

Tricyclic antidepressants (TCAs) represent the most commonly prescribed class for pain management, accounting for approximately 75% of antidepressant prescriptions according to a Quebec review. Dr. Jamal Hasoon, MD, an assistant professor at UTHealth Houston who directs the pain fellowship program, estimates TCAs make up at least half of such prescriptions in the United States.

Despite their widespread use, the evidence supporting TCAs is notably weak. The comprehensive review found:

Low certainty evidence for only three conditions: irritable bowel syndrome (IBS), neuropathic pain, and chronic tension-type headache
No effectiveness for chronic back pain, fibromyalgia, rheumatoid arthritis, or sciatica

Why do physicians continue prescribing TCAs so frequently? Hasoon offers insight: "Most of the benefits have been shown from the SNRI pathway, but tricyclics are just more commonly prescribed. My assumption is that tricyclics are older drugs, they're cheaper, and it's probably easier to get insurance to approve them."

SSRIs: The Serotonin Myth Debunked

Selective serotonin reuptake inhibitors (SSRIs) like Prozac (fluoxetine) and Zoloft (sertraline) are among the most prescribed antidepressants globally. However, when it comes to pain management, they appear largely ineffective.

The review found only low certainty evidence that SSRIs might help with depression accompanied by chronic pain. For all other pain conditions, there was simply no evidence of efficacy. This includes:

Back pain
Fibromyalgia
Chronic indigestion (functional dyspepsia)
Non-cardiac chest pain
Irritable bowel syndrome

"Most studies have shown that SSRIs only work on the serotonin pathway," Hasoon explains. "People typically don't get much response from that alone. They may help with depression symptoms, but it doesn't truly help with pain symptoms."

The Duloxetine Dose-Dilemma: Finding the Sweet Spot

A systematic review and meta-analysis published in October 2024 in the journal Pain Management examined nine randomized controlled trials involving 1,758 patients with chronic nonspecific low back pain. The study, conducted by researchers at Federal University of Bahia in Brazil, provides crucial guidance on duloxetine dosing.

Key findings:

Duloxetine 60 mg: Significant pain reduction (mean difference = -0.57; 95% CI: -0.78 to -0.36) with improved quality of life
Duloxetine 120 mg: Associated with increased adverse events and higher discontinuation rates (24.1% vs. 8.5% for placebo)

The researchers concluded that 60 mg provides the optimal balance between efficacy and tolerability. Higher doses, while potentially offering marginally better pain relief, significantly increase the risk of side effects including nausea, dizziness, dry mouth, and somnolence.

Special Considerations for Older Adults

Research published in September 2024 by the University of Sydney highlighted a concerning gap in evidence for older adults. Dr. Sujita Narayan and Associate Professor Christina Abdel Shaheed's study revealed that in the past 40 years, only 15 trials globally have focused specifically on antidepressants for pain in people over 65.

Their findings are particularly important:

No trials examined antidepressants for acute pain in older adults
International guidelines recommending antidepressants are based on studies that exclude or include few older participants
Older adults experience more adverse effects: falls, dizziness, and injuries
Discontinuation rates were higher than placebo groups

The study did identify one exception: duloxetine showed effectiveness for knee osteoarthritis pain in older adults during intermediate-term use (2-4 months), though benefits were modest and not sustained beyond 12 months.

"Withdrawal from antidepressants can be as bad as withdrawal from opioids," Dr. Narayan warns. "Anyone considering discontinuing should consult with their clinician and devise a tapering plan."

Understanding Why Antidepressants Sometimes Work for Pain

The exact mechanism by which certain antidepressants alleviate pain remains incompletely understood, but leading theories point to neurotransmitter modulation in the central nervous system.

Chronic pain involves complex pathways that extend beyond simple nerve damage or inflammation. The descending pain modulatory system, which originates in the brainstem, uses serotonin and norepinephrine to inhibit pain signals traveling to the brain. Antidepressants that increase these neurotransmitters may enhance this natural pain-inhibiting pathway.

"Chronic pain is such a complicated situation," Hasoon notes. "Even with our best scientific understanding of mechanism of action, there's so much at play. We have a decent understanding but don't have it completely figured out."

This complexity explains why antidepressants work better for certain types of pain:

Neuropathic pain (nerve damage): Often responds well to SNRIs and some TCAs
Mechanical pain (arthritis, musculoskeletal): Typically shows minimal response
Fibromyalgia: Mixed results, with SNRIs showing more promise than SSRIs

Beyond Medication: What Actually Works for Chronic Pain

Given the limited evidence for antidepressants, what should patients and providers turn to instead? The University of Sydney research strongly supports a multidimensional approach emphasizing non-pharmacological strategies.

Evidence-based alternatives include:

Physical exercise tailored to individual capabilities
Cognitive behavioral therapy (CBT) specifically designed for chronic pain
Mindfulness-based stress reduction
Graded activity programs
Physical therapy and rehabilitation
Sleep hygiene optimization

For older adults particularly, these approaches carry fewer risks and have demonstrated effectiveness in trials conducted specifically with this population.

Side Effects: The Hidden Cost of Trial-and-Error Prescribing

While patients wait to see if an antidepressant might help their pain, they often endure significant side effects. Common adverse events reported across studies include:

Duloxetine:

Nausea (13.7% incidence)
Dry mouth
Somnolence (drowsiness)
Dizziness
Constipation

TCAs:

Sedation
Weight gain
Orthostatic hypotension (blood pressure drop when standing)
Cardiac arrhythmias (particularly concerning in older adults)
Urinary retention
Sexual dysfunction

"If a patient is receiving treatment for which evidence is inconclusive, and there are other options available," Ferreira states, "I think it's reasonable to wait until we know more about the efficacy of certain treatments."

What This Means for Your Pain Management Plan

If you're living with chronic pain and currently taking antidepressants, or considering them as a treatment option, these research findings suggest several important conversations to have with your healthcare provider:

Ask about evidence: Request information about what studies support using a specific antidepressant for your particular pain condition.
Consider alternatives first: Discuss whether non-pharmacological approaches might be appropriate before or alongside medication trials.
Monitor closely: If you and your provider decide to try an antidepressant, track both pain levels and side effects carefully.
Don't stop abruptly: If discontinuing medication, work with your clinician on a gradual tapering plan to avoid withdrawal symptoms.
Age matters: Older adults should be particularly cautious, given the increased risk of falls and other adverse events.

The Path Forward: Better Research, Better Care

The research community recognizes significant gaps in our understanding of antidepressants for pain management. Key needs include:

More trials specifically including older adults
Longer-term studies examining sustained benefits
Independent research not funded by pharmaceutical companies
Head-to-head comparisons between different treatment approaches
Research on optimal dosing strategies

Until better evidence emerges, the current data suggests a more cautious, individualized approach to prescribing antidepressants for chronic pain—one that weighs modest potential benefits against well-documented risks and considers patients' unique circumstances.

References

Ferreira GE, Abdel-Shaheed C, Underwood M, et al. Efficacy, safety, and tolerability of antidepressants for pain in adults: overview of systematic reviews. BMJ. 2023;380:e072415. doi:10.1136/bmj-2022-072415
Nunes Filho MJLR, Barreto ESR, Antunes Júnior CR, et al. Efficacy of antidepressants in the treatment of chronic nonspecific low back pain: a systematic review and meta-analysis. Pain Manag. 2024 Oct;14(8):437-451. doi:10.1080/17581869.2024.2408215
Narayan S, Abdel Shaheed C, et al. Antidepressants prescribed for pain in older adults despite weak evidence of effectiveness. Br J Clin Pharmacol. 2024 Sep 13. Published online. doi:10.1111/bcp.16234
Yong RJ, Mullins PM, Bhattacharyya N. Prevalence of chronic pain among adults in the United States. Pain. 2022;163(2):e328-e332. doi:10.1097/j.pain.0000000000002291
Finnerup NB. Nonnarcotic methods of pain management. N Engl J Med. 2019;380(25):2440-2448. doi:10.1056/NEJMra1807061
Urits I, Peck J, Orhurhu MS, et al. Off-label antidepressant use for treatment and management of chronic pain: evolving understanding and comprehensive review. Curr Pain Headache Rep. 2019;23(9):66. doi:10.1007/s11916-019-0803-z

Sources Consulted:

Verywell Health: https://www.verywellhealth.com/antidepressant-chronic-pain-7152653
NCBI/PubMed Central: https://pmc.ncbi.nlm.nih.gov/articles/PMC11487954/
University of Sydney: https://www.sydney.edu.au/news-opinion/news/2024/09/13/antidepressants-prescribed-for-pain-in-older-adults-despite-weak.html

Disclaimer: This article is for informational purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider before making any changes to your medication or treatment plan. Individual responses to medications vary, and what works for one person may not work for another.